STAT3 and neoplasm: Given the pivotal roles the oncogenic STAT3 and EGFR pathways play in tumor development [8,9], we focused primarily on the repertoire of interleukin-6-like STAT3 activators and EGFR agonists secreted by tumor-primed monocytes and MΦ.